Further Exploration of the Benzimidazole Scaffold as TRPC5 Inhibitors: Identification of 1‐Alkyl‐2‐(pyrrolidin‐1‐yl)‐1H‐benzo[d]imidazoles as Potent and Selective Inhibitors

Abstract

The transient receptor potential cation channel 5 (TRPC5) plays an important role in numerous cellular processes. Due to this, it has gained considerable attention over the past few years as a potential therapeutic target. Recently, TRPC5 has been shown to be involved in the regulation of podocyte survival, indicating a potential treatment option for chronic kidney disease. In addition, a recent study has shown TRPC5 to be expressed in human sensory neurons and suggests that TRPC5 inhibition could be an effective treatment for spontaneous and tactile pain. To understand these processes more fully, potent and selective tool compounds are needed. Herein we report further exploration of the 2‐aminobenzimidazole scaffold as a potent TRPC5 inhibitor, culminating in the discovery of 16 f as a potent and selective TRPC5 inhibitor.

Nanomedicine in kidney disease

“…Compared with cancer and infectious disease, the utility of nanoparticles in kidney-related disorders has received considerably less attention. Though slowly and steadily, new therapeutics are being discovered for kidney disease, and simultaneous exploration of nanotechnology focused on kidney-targeted drug delivery systems should elevate the search for better and safer kidney medicine [6][7][8]. Here, were provide and updated review of recent seminal breakthroughs in the field of kidney disease-focused nanomedicine (Table 1).…”